An initiative of Flandersbio



in het nederlands in english informs you about important stock market related life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.


USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells


Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has decided to reject a new reexamination request of Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. The patent remains valid and enforceable.

“This is the fourth time that our US Patent for Production of Allogeneic TCR-Deficient CAR-T cells is challenged and each time, the USPTO has been favorable to Celyad. This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches and it places Celyad in a very good position to optimize the significant potential of its allogeneic platform, either on our own or through strategic collaborations”, said Christian Homsy, CEO of Celyad.

Source: Celyad

Back to top